Institutional shares held 29.7 Million
383K calls
1.22M puts
Total value of holdings $124M
$1.6M calls
$5.09M puts
Market Cap $262M
62,730,000 Shares Out.
Institutional ownership 47.27%
# of Institutions 139


Latest Institutional Activity in OMER

Top Purchases

Q2 2025
Morgan Stanley Shares Held: 1.36M ($5.67M)
Q2 2025
Two Sigma Investments, LP Shares Held: 670K ($2.8M)
Q2 2025
Deep Currents Investment Group LLC Shares Held: 528K ($2.21M)
Q2 2025
Two Sigma Advisers, LP Shares Held: 423K ($1.77M)
Q2 2025
Renaissance Technologies LLC Shares Held: 383K ($1.6M)

Top Sells

Q2 2025
Nomura Holdings Inc Shares Held: 88.6K ($370K)
Q2 2025
D. E. Shaw & Co., Inc. Shares Held: 1.65M ($6.89M)
Q2 2025
Ci Private Wealth, LLC Shares Held: 531K ($2.22M)
Q2 2025
Advisor Group Holdings, Inc. Shares Held: 229 ($957)
Q2 2025
State Street Corp Shares Held: 1.2M ($5.02M)

About OMER

Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.


Insider Transactions at OMER

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
0 Shares
From 0 Insiders
Sell / Disposition
0 Shares
From 0 Insiders

Track Institutional and Insider Activities on OMER

Follow OMEROS CORP and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells OMER shares.

Notify only if

Insider Trading

Get notified when an Omeros Corp insider buys or sells OMER shares.

Notify only if

News

Receive news related to OMEROS CORP

Track Activities on OMER